ALPL

Across TCGA pan-cancer cohorts, ALPL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ALPL data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ALPL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ALPL expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

LUAD, GBM, and PDAC are the cancer types where ALPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	II,III,IV	0.889	0.227	.002	19	view →
GBM	OS	Tertile	All	0.453	0.660	.004	18	view →
PDAC	OS	Quartile	II,III,IV	0.695	1.000	.008	18	view →
HNSC	OS	Tertile	All	0.796	0.575	.014	17	view →
LSCC	OS	Median	All	0.928	0.824	.007	8	view →
CCRCC	DFS	Quartile	III,IV	0.850	0.486	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ALPL–LUAD (DFS)

Open the LUAD breakdown →